Do Not Coadminister
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Dolutegravir/Abacavir/ Lamivudine (DTG/ABC/3TC)
Quality of Evidence:
Triumeq (dolutegravir, abacavir, lamivudine) is indicated for use as a complete regimen for the treatment of HIV-1 infection. Triumeq contains lamivudine and should not be taken with medicinal products containing emtricitabine due to the risk for intracellular interactions between cytidine analogues, such as lamivudine and emtricitabine.
Triumeq is not recommended for use in combination with emtricitabine containing products, since both lamivudine (in Triumeq) and emtricitabine are cytidine analogues (i.e. risk for intracellular interactions).
Triumeq Summary of Product Characteristics, ViiV Healthcare, June 2019.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking